Navigation Links
Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
Date:7/23/2013

seeking to enhance the immune system to combat cancer," commented Mark Fletcher, Generex's President & Chief Executive Officer.  "Recent announcements by Merck and Bristol-Myers Squibb of favourable clinical trial data suggest that immunotherapeutic drugs may significantly impact the treatment of cancer.  We look forward to additional data from the Antigen Express AE37 breast cancer vaccine trial this fall as we seek Phase III partnership opportunities in the context of the industry focus on immunotherapeutic treatments of cancer."

The Antigen Express AE37 vaccine is designed to stimulate the immune system to target HER2 on breast cancer cells at low levels independent of immune type of the person.  AE37 targets an early breast cancer patient population of unmet need several times larger than those treated with Herceptin.  In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional potential advantage is that the immunological memory induced by AE37 means the immune system may continue to scan for and kill HER2 cancer cells long after AE37 treatment has been completed.

Herceptin is approved for metastatic and early stage breast cancer patients. Its 2010 annual sales were nearly $6 Billion.  Given that the initial target population for AE37 in early stage breast cancer patients is twice that of Herceptin, the market potential for AE37 is clear.

About Generex Bio
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
2. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
3. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
4. Generex Announces Date of Annual Stockholders Meeting
5. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Secures Commitments for $3.6M Capital Raise
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
10. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Research and Markets ... the "Analysis of the Global Flow Cytometry ... Globally, flow cytometry remains a popular tool ... and stem cells. But the market is witnessing ... demand from underdeveloped nations to quantitate CD4 cell ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3
... March 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Lehman Brothers Global Healthcare Conference in Miami, will ... EDT. Kevin Hrusovsky, President and CEO of,Caliper, will ... The live,webcast can be accessed at, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=Caliper . ...
... biotech CEOs and,the president of one of the ... Greater Baltimore Committee as winners of the region,s ... Greater Baltimore Region Bioscience Awards are:, -- ... President & CEO, CSA,Medical, Inc. Askew,s very young ...
... 18 LigoCyte Pharmaceuticals,Inc., a vaccine company ... has,successfully finalized an agreement for a $28 ... development of its two lead vaccines,against norovirus ... is being led by Forward Ventures, JAFCO,and ...
Cached Biology Technology:Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round 2LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round 3
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... from Dr. Woodland,s lab at the Trudeau Institute have now ... blood cells to infected tissues and the ability of these ... infection has been cleared. The new data is featured on ... Medicine . "Defining the factors that regulate the generation ...
... rich in spices, like turmeric and cinnamon, reduces the body,s ... researchers. "Normally, when you eat a high-fat meal, you ... fat, in your blood," said Sheila West, associate professor of ... happens too frequently, or if triglyceride levels are raised too ...
... ability to detect the taste of iron in drinking water ... at risk for an unhealthy over-exposure to iron, Virginia Tech ... appears in the American Chemical Society,s journal Environmental Science ... , professor of civil and environmental engineering at Virginia Tech, ...
Cached Biology News:Antioxidant spices reduce negative effects of high-fat meal 2Fading ability to taste iron raises health concerns for people over age 50 2
IHC detection kit for BrdU in cells and tissues...
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
Biology Products: